A citation-based method for searching scientific literature

Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Larry Zhu, Shanshan Xiao, Xiaobin Yuan, Zhilin Shen, Li Zhang. J Thorac Oncol 2021
Times Cited: 12







List of co-cited articles
118 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
179
58

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
218
58

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
292
50

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Leora Horn, Jennifer G Whisenant, Heather Wakelee, Karen L Reckamp, Huan Qiao, Ticiana A Leal, Liping Du, Jennifer Hernandez, Vincent Huang, George R Blumenschein,[...]. J Thorac Oncol 2019
85
50

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
662
50

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
675
50

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
50

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Jessica J Lin, Viola W Zhu, Satoshi Yoda, Beow Y Yeap, Alexa B Schrock, Ibiayi Dagogo-Jack, Nicholas A Jessop, Ginger Y Jiang, Long P Le, Kyle Gowen,[...]. J Clin Oncol 2018
197
50

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
41

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
41

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
147
41

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
66
41

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
Ibiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, Catarina D Campbell, Jessica J Lin, Katherine R Schultz, Jennifer Ackil, Sara Stevens, Leila Dardaei, Satoshi Yoda,[...]. JCO Precis Oncol 2018
93
33

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
Tatsuya Yoshida, Yuko Oya, Kosuke Tanaka, Junichi Shimizu, Yoshitsugu Horio, Hiroaki Kuroda, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe. J Clin Oncol 2016
189
33

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
A Kron, C Alidousty, M Scheffler, S Merkelbach-Bruse, D Seidel, R Riedel, M A Ihle, S Michels, L Nogova, J Fassunke,[...]. Ann Oncol 2018
88
33

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J Herth, Claus P Heussel,[...]. Int J Cancer 2018
76
33

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
33

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
Isabella Zhang, Nicholas G Zaorsky, Joshua D Palmer, Ranee Mehra, Bo Lu. Lancet Oncol 2015
119
33

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino,[...]. Clin Cancer Res 2021
12
25

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
Yi-Long Wu, Shun Lu, You Lu, Jianying Zhou, Yuan-Kai Shi, Virote Sriuranpong, James C M Ho, Choo Khoon Ong, Chun-Ming Tsai, Chin-Hee Chung,[...]. J Thorac Oncol 2018
96
25

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao,[...]. Target Oncol 2019
27
25

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
Yuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, Wen-Zhao Zhong, Qing Zhou, Hai-Yan Tu, Hong-Xia Tian, Wei-Bang Guo, Lu-Lu Yang, Hong-Hong Yan,[...]. Clin Lung Cancer 2016
45
25

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Ka-Won Noh, Mi-Sook Lee, Seung Eun Lee, Ji-Young Song, Hyun-Tae Shin, Yu Jin Kim, Doo Yi Oh, Kyungsoo Jung, Minjung Sung, Mingi Kim,[...]. J Pathol 2017
51
25

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
Johannes Noé, Alex Lovejoy, Sai-Hong Ignatius Ou, Stephanie J Yaung, Walter Bordogna, Daniel M Klass, Craig A Cummings, Alice T Shaw. J Thorac Oncol 2020
25
25

Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yongfeng Yu, Qiuxiang Ou, Xue Wu, Hairong Bao, Yan Ding, Yang W Shao, Shun Lu. Lung Cancer 2019
25
25

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski,[...]. Cancer Discov 2018
156
25

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Richard Bayliss, Jene Choi, Dean A Fennell, Andrew M Fry, Mark W Richards. Cell Mol Life Sci 2016
61
25

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
C G Woo, S Seo, S W Kim, S J Jang, K S Park, J Y Song, B Lee, M W Richards, R Bayliss, D H Lee,[...]. Ann Oncol 2017
147
25

ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Xue Du, Yun Shao, Hai-Feng Qin, Yan-Hong Tai, Hong-Jun Gao. Thorac Cancer 2018
101
25

Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
Difan Zheng, Rui Wang, Yang Zhang, Yunjian Pan, Xinghua Cheng, Chao Cheng, Shanbo Zheng, Hang Li, Ranxia Gong, Yuan Li,[...]. J Cancer Res Clin Oncol 2016
14
25

Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055).
Meichen Li, Xue Hou, Chengzhi Zhou, Weineng Feng, Guanming Jiang, Hao Long, Shuang Yang, Jing Chen, Na Wang, Kaicheng Wang,[...]. Front Oncol 2020
8
37

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se-Hoon Lee, Lilian Bu,[...]. Lancet Respir Med 2019
107
25

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
460
25

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.
Laura Mezquita, Aurélie Swalduz, Cécile Jovelet, Sandra Ortiz-Cuaran, Karen Howarth, David Planchard, Virginie Avrillon, Gonzalo Recondo, Solène Marteau, Jose Carlos Benitez,[...]. JCO Precis Oncol 2020
28
25

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, Karen L Reckamp, Karin Holmskov Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, Harry J M Groen, Maximilian J Hochmair,[...]. J Clin Oncol 2017
373
25

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
Caroline E McCoach, Collin M Blakely, Kimberly C Banks, Benjamin Levy, Ben M Chue, Victoria M Raymond, Anh T Le, Christine E Lee, Joseph Diaz, Saiama N Waqar,[...]. Clin Cancer Res 2018
107
25

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
550
25

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa,[...]. Cancer Sci 2020
27
25

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec,[...]. Clin Cancer Res 2020
67
25

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, Alberto A Chiappori, Howard L West, Michele C Azada, Peter N Morcos, Ruey-Min Lee, Linta Garcia, Li Yu,[...]. Lancet Oncol 2014
508
25

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Makoto Nishio, Tatsuya Yoshida, Toru Kumagai, Toyoaki Hida, Ryo Toyozawa, Tadasuke Shimokawaji, Koichi Goto, Kazuhiko Nakagawa, Yuichiro Ohe, Takashi Seto,[...]. J Thorac Oncol 2021
30
25

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Alice T Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok,[...]. Lancet Oncol 2017
329
25

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Mohammad Jahanzeb, Huamao M Lin, Xiaoyun Pan, Yu Yin, Pia Baumann, Corey J Langer. Clin Lung Cancer 2021
21
25

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.
Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, Rebecca J Nagy, Beow Y Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F Farago, Aaron N Hata,[...]. Clin Cancer Res 2019
78
25

Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw. Cancer Discov 2017
291
25

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Melissa West, Ruth W Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang,[...]. Cancer Cell 2015
291
25

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Rudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, Howard L West, Karen L Reckamp, Natasha B Leighl, Marcello Tiseo, Egbert F Smit, Dong-Wan Kim, Scott N Gettinger,[...]. J Thorac Oncol 2020
72
25

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario Garcia Campelo, Dong-Wan Kim,[...]. J Thorac Oncol 2021
43
25

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
25

Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.
P Christopoulos, M Kirchner, F Bozorgmehr, V Endris, M Elsayed, J Budczies, J Ristau, R Penzel, F J Herth, C P Heussel,[...]. Int J Cancer 2019
50
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.